Lineage Cell Therapeutics Investor Relations Material
Latest events
Q4 2024
Lineage Cell Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Lineage Cell Therapeutics Inc
Access all reports
Lineage Cell Therapeutics, Inc., a biotechnology company, develops cell therapies for the treatment of degenerative diseases. The company develops allogeneic cellular therapies from immortally differentiated human cells. It is developing VAC, an allogeneic cancer immunotherapy for the treatment of solid tumors; OPREGEN, an allogeneic retinal pigment epithelial cell product for the treatment of dry age-related macular degeneration, as well as wet age-related macular degeneration and diabetic eye diseases; Neo-Kidney Augment, an allogeneic product candidate that is in preclinical study to treat subjects with end stage renal disease.
Latest articles
)
Moncler: From the Mountains to the Runway
The story of Moncler, all the way from its beginnings in the Alps to its journey to some of the most prestigious runways in the world.
16 Apr 2025
)
eToro: Innovation, Growth, and IPO Plans
eToro was founded in 2007 and has grown into a global trading platform with over 40 million users and an extensive offering across several asset classes.
10 Apr 2025
)
Yum! Brands: The Company Behind Pizza Hut, KFC, and Taco Bell
Yum! Brands started at PepsiCo in the 1970s and is home to some of the most well-known brands in the world, such as Pizza Hut, KFC, and Taco Bell.
9 Apr 2025
Ticker symbol
LCTX
Country
🇺🇸 United States